Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Rhei granted marketing approval for MuGard in China

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, Rhei Pharmaceuticals HK Ltd., received regulatory and marketing approval for MuGard in China from the State Food and Drug Administration, or SFDA, to treat oral mucositis in cancer patients.

24 Feb 2012

FDA, pharmaceutical companies announce solution to cancer drug shortage

The U.S. Food and Drug Administration and several pharmaceutical companies said Tuesday they have reached agreements to alleviate shortages for the drugs methotrexate and Doxil. Methotrexate is used to treat children with a form of leukemia and others with tumors of the breast and lungs. Doxil is used to treat ovarian cancer and multiple myeloma.

23 Feb 2012

FDA approves new supplies of drugs that are facing shortages

The United States Food and Drugs Administration (FDA) have approved new suppliers for two crucial cancer drugs, easing critical shortages that had been concerning patients and families particularly of the children with leukemia. But there are currently 283 separate prescription drugs in short supply or unavailable nationwide, and regulators and manufacturers say shortages are a long-term problem that will continue to scare patients and doctors.

22 Feb 2012

Bid to raise awareness of risks and symptoms of ovarian cancer: The 2012 Teal Ribbon Day

Ovarian Cancer Australia has found less than one per cent of women know they're at risk if there's a family history of ovarian cancer on their father's side. And only 42 per cent know a history on their mother's side puts them at increased risk.

22 Feb 2012

Simple blood test may provide early detection of cancer

A simple blood test is being developed by researchers at Ben-Gurion University of the Negev (BGU) and Soroka University Medical Center in Beer-Sheva, Israel that may provide early detection of many types of cancer.

22 Feb 2012

OGF-OGFr axis discovery provides new insights into ovarian cancer

Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that the presence and integrity of the opioid growth factor receptor (OGFr), which mediates the inhibitory action of opioid growth factor (OGF) on cell proliferation, is a key to understanding the progression and treatment of human ovarian cancer.

22 Feb 2012

Targeting patient's own dendritic cells may help restore the immune system

Aggressive ovarian tumors begin as malignant cells kept in check by the immune system until, suddenly and unpredictably, they explode into metastatic cancer. New findings from scientists at The Wistar Institute demonstrate that ovarian tumors don't necessarily break "free" of the immune system, rather dendritic cells of the immune system seem to actively support the tumor's escape.

20 Feb 2012

Study identifies USP15 as a critical protein in cancer

After years studying the molecular bases of glioblastoma - the most common brain tumor and one of the most aggressive of all cancers, the group led by Dr. Joan Seoane , Director of Translational Research at the Vall d'Hebron Institute of Oncology (VHIO) and ICREA Research Professor has today published a study in Nature Medicine identifying USP15 as a critical protein in cancer which, thanks to its molecular characteristics, shows enormous therapeutic promise.

20 Feb 2012

Cryoablation increases survival rates in ovarian cancer patients

Ovarian cancer, which killed 15,000 American women last year, is one of the deadliest forms of cancer. A team of Wayne State University School of Medicine researchers recently proved that freezing tumors increases survival rates in ovarian cancer patients.

17 Feb 2012

Drugmaker warns that fake cancer drug is on the market

The Wall Street Journal reports that the manufacturer of Avastin says it has found counterfeit vials of the drug in the United States.

16 Feb 2012

Thrombocytosis linked to severity of ovarian cancer

Highly elevated platelet levels fuel tumor growth and reduce the survival of ovarian cancer patients, an international team of researchers led by scientists at The University of Texas MD Anderson Cancer center reports in the New England Journal of Medicine.

16 Feb 2012

Ovarian cancer subtype may be susceptible to 'anti-angiogenic' drugs

Scientists at Dana-Farber Cancer Institute have identified a subtype of ovarian cancer able to build its own blood vessels, suggesting that such tumors might be especially susceptible to "anti-angiogenic" drugs that block blood vessel formation.

15 Feb 2012

Study finds BRCA1 mutations in nearly one in five TN breast cancer patients

Leading breast cancer experts are calling for women under 50 who are diagnosed with triple-negative (TN) breast cancer to be offered testing for faults in the BRCA1 gene, according to a report published in the British Journal of Cancer.

15 Feb 2012

Researchers investigate role of a MYC family gene in ovarian cancer

The role of a known cancer-causing gene in the development of the most lethal type of ovarian cancer is being investigated by researchers from the Walter and Eliza Hall Institute after they were awarded a Cure Cancer Australia Foundation (CCAF) grant.

15 Feb 2012

Study confirms increased risk of cancers linked with Lynch syndrome

People with Lynch syndrome have a genetic mutation that gives them a high risk of several types of cancer including bowel cancer. The genes that are damaged can't repair any errors that occur in our DNA.

15 Feb 2012

Diffusion-weighted MRI may effectively indicate response to ovarian cancer treatment

Cancer Research UK-funded scientists have determined that a magnetic resonance imaging (MRI) technique, which measures the movement of water molecules within the tumour, may be the best way to monitor how women with late-stage ovarian cancer are responding to treatment. The study is published in the journal Radiology today.

14 Feb 2012

People with Lynch syndrome face increased risks of breast and pancreatic cancers

A new prospective study of patients with Lynch syndrome - an inherited disorder of cancer susceptibility caused by mutations in specific DNA repair genes - provides the first strong evidence that people with Lynch syndrome face significantly increased risks of breast and pancreatic cancers.

14 Feb 2012

New software key for personalized cancer medicine

High-throughput DNA sequencing technologies are leading to a revolution in how clinicians diagnose and treat cancer. The molecular profiles of individual tumors are beginning to be used in the design of chemotherapeutic programs optimized for the treatment of individual patients.

14 Feb 2012

Study demonstrates dynamic genetic changes in ovarian cancers between diagnosis and recurrence

There is a need to analyze tumor specimens at the time of ovarian cancer recurrence, according to a new study published in Molecular Cancer Therapeutics.

13 Feb 2012

Two new cancer research laboratories at WEHI receive $2M ACRF funding

The Australian Cancer Research Foundation (ACRF) has committed $2 million towards the fit-out of two new cancer research laboratories at the Walter and Eliza Hall Institute.

9 Feb 2012